EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tissue‐Engineered Disease Modeling of Lymphangioleiomyomatosis Exposes a Therapeutic Vulnerability to HDAC Inhibition

Adam Pietrobon, Julien Yockell-Lelièvre, Nicole Melong, Laura J Smith, Sean P Delaney, Nadine Azzam, Chang Xue, Nishanth Merwin, Eric Lian, Alberto Camacho-Magallanes, Carole Doré, Gabriel Musso und 6 weitere

Advanced Science · 2023

DOI: 10.1002/advs.202302611 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2023. Verfasst von Adam Pietrobon und 17 weiteren Autor:innen. Beteiligte Einrichtung: The Sprott Centre for Stem Cell Research, Regenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, K1Y 4E9, Canada. Hauptthemen laut MEDLINE: Lymphangioleiomyomatosis, Lung Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ontario Institute for Cancer Research, Canadian Institutes for Health Research, CIHR Vanier Canada Graduate Scholarship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lymphangioleiomyomatosis (LAM) is a rare disease involving cystic lung destruction by invasive LAM cells. These cells harbor loss‐of‐function mutations in TSC2 , conferring hyperactive mTORC1 signaling. Here, tissue engineering tools are employed to model LAM and identify new therapeutic candidates. Biomimetic hydrogel culture of LAM cells is found to recapitulate the molecular and phenotypic characteristics of human disease more faithfully than culture on plastic. A 3D drug screen is conducted, identifying histone deacetylase (HDAC) inhibitors as anti‐invasive agents that are also selectively cytotoxic toward TSC2 −/− cells. The anti‐invasive effects of HDAC inhibitors are independent of genotype, while selective cell death is mTORC1‐dependent and mediated by apoptosis. Genotype‐selective cytotoxicity is seen exclusively in hydrogel culture due to potentiated differential mTORC1 signaling, a feature that is abrogated in cell culture on plastic. Importantly, HDAC inhibitors block invasion and selectively eradicate LAM cells in vivo in zebrafish xenografts. These findings demonstrate that tissue‐engineered disease modeling exposes a physiologically relevant therapeutic vulnerability that would be otherwise missed by conventional culture on plastic. This work substantiates HDAC inhibitors as possible therapeutic candidates for the treatment of patients with LAM and requires further study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LymphangioleiomyomatosisLung NeoplasmsAnimalsHumansHistone Deacetylase InhibitorsTissue EngineeringZebrafishMechanistic Target of Rapamycin Complex 1

Stichwörter der Autor:innen

3D drug screenHDAC inhibitionbiomimetic hydrogel culturelymphangioleiomyomatosismTORC1therapeutics developmentzebrafish

Substanzen

Histone Deacetylase InhibitorsMechanistic Target of Rapamycin Complex 1

Autor:innen und Institutionen

  • The Sprott Centre for Stem Cell Research, Regenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, K1Y 4E9, Canada.
  • Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, K1N 6N5, Canada.
  • Ottawa Institute of Systems Biology, Ottawa, K1H 8M5, Canada.
  • Department of Pediatrics, CHEO Research Institute, Ottawa, K1H 5B2, Canada.
  • Department of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, M5S 3E5, Canada.
  • Institute for Biomaterials and Biomedical Engineering, University of Toronto, Toronto, M5S 3G9, Canada.

ORCID-Profile: William L Stanford

Förderung

  • Ontario Institute for Cancer Research
  • Canadian Institutes for Health Research
  • CIHR Vanier Canada Graduate Scholarship
  • Canada Research Chairs
  • LAM Foundation

Zitieren

APA

Pietrobon, A., Yockell-Lelièvre, J., Melong, N., Smith, L. J., Delaney, S. P., Azzam, N., Xue, C., Merwin, N., Lian, E., Camacho-Magallanes, A., Doré, C., Musso, G., Julian, L. M., Kristof, A. S., Tam, R. Y., Berman, J. N., Shoichet, M. S., & Stanford, W. L. (2023). Tissue‐Engineered Disease Modeling of Lymphangioleiomyomatosis Exposes a Therapeutic Vulnerability to HDAC Inhibition. Advanced Science. https://doi.org/10.1002/advs.202302611

Vancouver

Pietrobon A, Yockell-Lelièvre J, Melong N, Smith LJ, Delaney SP, Azzam N, et al. Tissue‐Engineered Disease Modeling of Lymphangioleiomyomatosis Exposes a Therapeutic Vulnerability to HDAC Inhibition. Advanced Science. 2023. doi:10.1002/advs.202302611

BibTeX
@article{Pietrobon2023,
  author = {Pietrobon, Adam and Yockell-Lelièvre, Julien and Melong, Nicole and Smith, Laura J and Delaney, Sean P and Azzam, Nadine and Xue, Chang and Merwin, Nishanth and Lian, Eric and Camacho-Magallanes, Alberto and Doré, Carole and Musso, Gabriel and Julian, Lisa M and Kristof, Arnold S and Tam, Roger Y and Berman, Jason N and Shoichet, Molly S and Stanford, William L},
  title = {Tissue‐Engineered Disease Modeling of Lymphangioleiomyomatosis Exposes a Therapeutic Vulnerability to HDAC Inhibition},
  journal = {Advanced Science},
  year = {2023},
  doi = {10.1002/advs.202302611}
}
Kostenlos starten →